Relmada Therapeutics Inc

NASDAQ RLMD

Data sourced from

and

Download Data

Relmada Therapeutics Inc Cash and Short-Term Investments for the quarter ending March 31, 2024: USD 83.61 M

Relmada Therapeutics Inc Cash and Short-Term Investments is USD 83.61 M for the quarter ending March 31, 2024, a -36.87% change year over year. Cash and Short-Term Investments is the sum of cash and short-term investments, representing the company's liquid assets.

Relmada Therapeutics Inc Cash and Short-Term Investments for the quarter ending March 31, 2023 was USD 132.44 M, a -39.98% change year over year.
Relmada Therapeutics Inc Cash and Short-Term Investments for the quarter ending March 31, 2022 was USD 220.65 M, a 114.84% change year over year.
Relmada Therapeutics Inc Cash and Short-Term Investments for the quarter ending March 31, 2021 was USD 102.70 M, a -10.63% change year over year.
Relmada Therapeutics Inc Cash and Short-Term Investments for the quarter ending March 31, 2020 was USD 114.92 M, a 5,495.19% change year over year.

NASDAQ: RLMD

Relmada Therapeutics Inc

CEO	Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD
IPO Date	Oct. 9, 2014
Location	United States
Headquarters	2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134
Employees	20
Sector	Healthcare
Industry	Biotechnology

Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Key trends